Do analysts recommend SBTX or DRUG?

Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 177.67%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bright Minds Biosciences 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has better earnings and valuation, SBTX or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is SBTX or DRUG more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Bright Minds Biosciences N/A -12.46% -12.30%

Do analysts recommend AQST or SBTX?

Aquestive Therapeutics currently has a consensus price target of $9.17, indicating a potential upside of 95.87%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate OCS or SBTX?

Oculis currently has a consensus target price of $39.44, indicating a potential upside of 325.51%. Given Oculis' stronger consensus rating and higher probable upside, equities analysts clearly believe Oculis is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate TLRY or SBTX?

Tilray Brands currently has a consensus price target of $7.00, indicating a potential upside of 69.49%. Given Tilray Brands' stronger consensus rating and higher possible upside, research analysts clearly believe Tilray Brands is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend SBTX or EOLS?

Evolus has a consensus price target of $14.50, indicating a potential upside of 81.93%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Silverback Therapeutics (SBTX) Competitors

$4.08 -0.07 (-1.69%)

As of 09/25/2026

Compare

SBTX vs. DRUG, AQST, OCS, TLRY, and EOLS

Should you buy Silverback Therapeutics stock or one of its competitors? Silverback Therapeutics's main competitors and comparable companies include Bright Minds Biosciences (DRUG), Aquestive Therapeutics (AQST), Oculis (OCS), Tilray Brands (TLRY), and Evolus (EOLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Silverback Therapeutics compare to Bright Minds Biosciences?

Silverback Therapeutics (NASDAQ:SBTX) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Bright Minds Biosciences' return on equity of -12.46% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 177.67%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, indicating that its share price is 636% less volatile than the broader market.

In the previous week, Bright Minds Biosciences had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Bright Minds Biosciences and 0 mentions for Silverback Therapeutics. Bright Minds Biosciences' average media sentiment score of 1.07 beat Silverback Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Bright Minds Biosciences	Positive

Summary

Bright Minds Biosciences beats Silverback Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Silverback Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Aquestive Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Aquestive Therapeutics and 0 mentions for Silverback Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.82 beat Silverback Therapeutics' score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Very Positive
Silverback Therapeutics	Neutral

Aquestive Therapeutics has higher revenue and earnings than Silverback Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$54.09M	10.86	-$83.78M	-$0.65	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Aquestive Therapeutics currently has a consensus price target of $9.17, indicating a potential upside of 95.87%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silverback Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Silverback Therapeutics	N/A	-29.62%	-28.20%

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aquestive Therapeutics beats Silverback Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Silverback Therapeutics compare to Oculis?

Oculis (NASDAQ:OCS) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Oculis has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Silverback Therapeutics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	370.67	-$119.44M	-$1.74	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, Oculis had 5 more articles in the media than Silverback Therapeutics. MarketBeat recorded 5 mentions for Oculis and 0 mentions for Silverback Therapeutics. Oculis' average media sentiment score of 0.46 beat Silverback Therapeutics' score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company	Overall Sentiment
Oculis	Neutral
Silverback Therapeutics	Neutral

22.3% of Oculis shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Silverback Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Silverback Therapeutics' return on equity of -29.62% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Oculis currently has a consensus target price of $39.44, indicating a potential upside of 325.51%. Given Oculis' stronger consensus rating and higher probable upside, equities analysts clearly believe Oculis is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Silverback Therapeutics beats Oculis on 8 of the 15 factors compared between the two stocks.

How does Silverback Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Silverback Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Tilray Brands' return on equity of -7.76% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Tilray Brands has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Silverback Therapeutics has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$210.48M	2.67	-$121.40M	-$1.08	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, Tilray Brands had 21 more articles in the media than Silverback Therapeutics. MarketBeat recorded 21 mentions for Tilray Brands and 0 mentions for Silverback Therapeutics. Tilray Brands' average media sentiment score of 0.26 beat Silverback Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Tilray Brands	Neutral
Silverback Therapeutics	Neutral

Tilray Brands currently has a consensus price target of $7.00, indicating a potential upside of 69.49%. Given Tilray Brands' stronger consensus rating and higher possible upside, research analysts clearly believe Tilray Brands is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Tilray Brands beats Silverback Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Silverback Therapeutics compare to Evolus?

Silverback Therapeutics (NASDAQ:SBTX) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Silverback Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Evolus' return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Evolus	-10.85%	N/A	-13.00%

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Evolus has a consensus price target of $14.50, indicating a potential upside of 81.93%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Evolus had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 2 mentions for Evolus and 0 mentions for Silverback Therapeutics. Evolus' average media sentiment score of 0.91 beat Silverback Therapeutics' score of 0.00 indicating that Evolus is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Evolus	Positive

Evolus has higher revenue and earnings than Silverback Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Evolus	$297.18M	1.77	-$51.64M	-$0.52	N/A

Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Evolus has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Summary

Evolus beats Silverback Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$147.12M	$12.68B	$7.33B	$13.17B
Dividend Yield	N/A	2.63%	2.52%	14.03%
P/E Ratio	-1.69	797.38	275.82	25.78
Price / Sales	N/A	792.71	650.06	92.83
Price / Cash	N/A	89.30	79.52	52.89
Price / Book	0.55	10.54	10.44	6.30
Net Income	-$89.48M	$2.85B	$3.51B	$360.35M
7 Day Performance	-0.73%	-1.10%	-1.31%	-0.23%
1 Month Performance	-32.34%	-3.06%	-4.61%	-4.16%
1 Year Performance	-58.37%	1.28%	15.01%	4.58%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$4.08 -1.7%	N/A	-57.2%	$147.12M	N/A	N/A	83	High Trading Volume
DRUG Bright Minds Biosciences	2.4251 of 5 stars	$61.55 +4.1%	$143.83 +133.7%	-1.7%	$598.88M	N/A	N/A	25	News Coverage Positive News
AQST Aquestive Therapeutics	2.3128 of 5 stars	$4.66 -3.3%	$9.17 +96.7%	-21.9%	$584.88M	$44.54M	N/A	147	Gap Up
OCS Oculis	2.1124 of 5 stars	$9.98 +0.7%	$38.00 +280.8%	-47.4%	$578.64M	$1.45M	N/A	60	News Coverage Gap Up
TLRY Tilray Brands	3.7343 of 5 stars	$3.94 +0.3%	$8.00 +103.0%	-64.1%	$535.28M	$210.48M	N/A	3,595

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. DRUG, AQST, OCS, TLRY, and EOLS

How does Silverback Therapeutics compare to Bright Minds Biosciences?

Summary

How does Silverback Therapeutics compare to Aquestive Therapeutics?

Summary

How does Silverback Therapeutics compare to Oculis?

Summary

How does Silverback Therapeutics compare to Tilray Brands?

Summary

How does Silverback Therapeutics compare to Evolus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. DRUG, AQST, OCS, TLRY, and EOLS

How does Silverback Therapeutics compare to Bright Minds Biosciences?

Is SBTX or DRUG more profitable?

Which has better earnings and valuation, SBTX or DRUG?

Do institutionals & insiders hold more shares of SBTX or DRUG?

Do analysts recommend SBTX or DRUG?

Which has more risk and volatility, SBTX or DRUG?

Does the media refer more to SBTX or DRUG?

Summary

How does Silverback Therapeutics compare to Aquestive Therapeutics?

Which has more volatility and risk, AQST or SBTX?

Does the media favor AQST or SBTX?

Which has stronger valuation and earnings, AQST or SBTX?

Do analysts recommend AQST or SBTX?

Is AQST or SBTX more profitable?

Do insiders & institutionals believe in AQST or SBTX?

Summary

How does Silverback Therapeutics compare to Oculis?

Which has more risk and volatility, OCS or SBTX?

Which has higher valuation and earnings, OCS or SBTX?

Does the media refer more to OCS or SBTX?

Do institutionals and insiders believe in OCS or SBTX?

Is OCS or SBTX more profitable?

Do analysts rate OCS or SBTX?

Summary

How does Silverback Therapeutics compare to Tilray Brands?

Is TLRY or SBTX more profitable?

Which has more volatility and risk, TLRY or SBTX?

Do institutionals & insiders have more ownership in TLRY or SBTX?

Which has better valuation & earnings, TLRY or SBTX?

Does the media favor TLRY or SBTX?

Do analysts rate TLRY or SBTX?

Summary

How does Silverback Therapeutics compare to Evolus?

Is SBTX or EOLS more profitable?

Do institutionals and insiders believe in SBTX or EOLS?

Do analysts recommend SBTX or EOLS?

Does the media prefer SBTX or EOLS?

Which has preferable valuation & earnings, SBTX or EOLS?

Which has more volatility & risk, SBTX or EOLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools